SCHEMBL26313878

SCHEMBL26313878

CC(C)(C)OC(=O)NCCN(Cc1cc(Cl)ccc1Br)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.44
HTT P42858 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 2/20 0.43
GAA P10253 2/20 0.43
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
KDM4E B2RXH2 2/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
CYP2C9 P11712 1/20 0.39
PTGER1 P34995 1/20 0.39
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26313896 0.88 IDO1 (0.45) IDO1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL30597398 0.87 NOS2 (0.43) IDO1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL26313794 0.87 NOS2 (0.43) IDO1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL26313870 0.80 TSHR (0.45) IDO1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL20313968 0.80 MTNR1A (0.54) IDO1CKS1BSKP1SKP2CTSS
SCHEMBL29793580 0.77 GAA (0.49) IDO1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL4757294 0.77 GAA (0.49) IDO1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL8399559 0.77 MAPT (0.54) IDO1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL18106066 0.76 IDO1 (0.46) IDO1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL30597303 0.75 IDO1 (0.43) IDO1HTTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286913-A1 INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF Gacter Inc. (US) 2023-09-14 US disclosed
US-20230286913-A1 INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF Gacter Inc. (US) 2023-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286913-A1 INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF NOS1, NOS3, NOS2 IDO1 68/4885HTT 2867/4885MEN1 2794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.